Indeed, while we did not observe statistically significant changes to the T‐cell subtype populations, the CD8+/Treg ratio was significantly higher in NTP‐treated mice (Figure 5c), which is advantageous for developing robust anti‐cancer immunity. This evidence concerns the gene CD8A and cancer.